News and Insights from Our Multidisciplinary Team of Experts
Unlocking the combined value of Offspring’s innovative pre-clinical solutions with Flagship’s clinical trial data-driven assay solutions. Broomfield, CO, USA and Södertälje, Sweden – January 23, 2024 – Flagship Biosciences, a leader in spatial biology and biomarker...
We are honored to announce that Flagship Biosciences has earned a Frost & Sullivan 2023 North American Customer Value Leadership Award in the AI-enabled digital pathology solutions market. Following from detailed evaluation of best practices criteria, the award...
Genomenon’s genomic landscapes enhance Flagship’s biomarker services and companion diagnostic development solutions
Broomfield, CO and Ann Arbor, MI – February 7, 2023 – Flagship Biosciences, a leader in spatial biology and biomarker analytics services, today announced a strategic partnership…
Accomplished industry executive strengthens company’s position as a leader in spatial biology and biomarker analytics.BROOMFIELD, CO - September 27, 2022 — Flagship Biosciences, Inc., a leader in spatial biology and biomarker analytics services, announced the hiring...
Acquisition significantly expands Flagship’s portfolio of biomarker and analytics servicesBroomfield, CO – August 31, 2022 — Flagship Biosciences, Inc., a leader in spatial biology and biomarker analytics services, announced the acquisition of Interpace Pharma...
The journal Scientific Reports recently published a manuscript on the validation of Flagship’s new digital assay, Tissue Insight (TI) 22C3 NSCLC.1 This technology facilitates the otherwise cumbersome process of quantifying programmed cell death ligand 1 (PD-L1)...
Sign up to receive industry and company news, including The Cut Point, Flagship’s quarterly e-newsletter.
PUBLICATIONS/POSTERS
Abstract: The anti-PD-L1 antibody (22C3) is used as a companion diagnostic for successful checkpoint inhibitor therapy in head and neck squamous cell carcinoma. The positive predictive value of this assay, however, is less than ideal as a high PD-L1 score does not...
Key Takeaways CRC patient survival correlates with the presence or absence of macrophage biomarkers CD68, CD163, and a lack of PD-L1. Lower levels of ‘M1/anti-tumor’ CD68+ or CD68+CD163– cells correlate with increased survival. Higher levels of ‘M2/pro-tumor’ CD163+...
Key Takeaways Image analysis is able to use immune biomarkers to correlate immune cell presence and localization with patient survival in NSCLC. Patient survival correlates with the presence or absence of CD68 and CD163 macrophage markers, but these markers do not...
EVENTS
Meet with us at booth #25. As a Gold Sponsor for the third annual Spatial Biology East Coast Congress in Boston, we hope you’ll join our experts and over 350 other industry leaders to discuss the transforming field of spatial biology. Examine how spatial biology can...
Meet with us at booth #37085. We help you analyze more data in more depth, so you can produce more effective therapies. Attending the 2024 ASCO® Annual Meeting? Schedule a meeting with our team to discuss our: AI-powered digital pathology solutions Biomarker...
Are you attending the 2024 ASGCT Annual Meeting? With field-leading keynotes, 200+ scientific sessions, over 7,000 researchers in attendance, and an expanded exhibit hall, the 27th American Society of Gene and Cell Therapy Annual Meeting is the nexus for gene and cell...